The transmucosal drug delivery devices market size has grown strongly in recent years. It will grow from $54.63 billion in 2025 to $59.61 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to expansion of non-invasive drug delivery approaches, rising demand for pain management therapies, increased use of hormone replacement treatments, growth in pharmaceutical formulation innovation, wider acceptance of transmucosal therapies.
The transmucosal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $81.52 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing development of personalized medicine solutions, rising investments in advanced drug delivery platforms, growing demand for at-home drug administration devices, expansion of biologics and peptide-based drugs, increased regulatory approvals for novel delivery systems. Major trends in the forecast period include increasing adoption of buccal and sublingual delivery formats, growing demand for rapid onset drug administration, expansion of microneedle and active delivery technologies, rising focus on patient-friendly drug delivery devices, enhanced emphasis on dose accuracy and bioavailability.
The increasing prevalence of chronic diseases is expected to drive the growth of the transmucosal drug delivery devices market in the coming years. Chronic diseases are long-lasting conditions that typically develop gradually and persist over time, often requiring ongoing medical management to control symptoms and prevent complications. The rise in chronic diseases can be attributed to factors such as lifestyle choices, aging populations, environmental influences, challenges within healthcare systems, and urbanization. Transmucosal drug delivery devices are employed in managing chronic diseases by providing controlled and efficient medication delivery, ensuring sustained therapeutic levels to manage symptoms and enhance patient adherence. For example, in August 2023, a report from the Leukemia & Lymphoma Society (LLS), a US-based nonprofit organization, indicated that in the US, a person is diagnosed with leukemia, lymphoma, or myeloma approximately every three minutes. In 2023, an estimated 184,720 individuals were expected to be diagnosed, accounting for 9.4% of the projected 1,958,310 new cancer cases for the year. Therefore, the rising prevalence of chronic diseases is fueling the growth of the transmucosal drug delivery devices market.
Leading companies in the transmucosal drug delivery devices sector are actively pursuing innovative solutions such as proprietary transdermal patch delivery platforms, which are designed to improve drug absorption, enhance patient compliance, and offer convenience. These platforms utilize specialized technologies owned by companies to administer medications through the skin, ensuring controlled release and optimized therapeutic outcomes. For example, in January 2024, Starton Therapeutics Inc., a US-based biotechnology firm, introduced STARSILON, a novel proprietary transdermal patch delivery platform. This platform is specifically designed to deliver difficult-to-formulate active pharmaceutical ingredients (APIs) over an extended period, thereby expanding the options for transdermal drug delivery and enhancing therapeutic efficacy through sustained release mechanisms.
In April 2023, Difgen Pharmaceuticals, an India-based pharmaceutical company, acquired Aveva Drug Delivery Services for an undisclosed sum. This strategic acquisition is intended to bolster Difgen Pharmaceuticals' drug delivery capabilities and incorporate advanced technologies into its pharmaceutical product portfolio. Aveva Drug Delivery Services, based in the US, specializes in manufacturing transdermal delivery systems (TDS) and oral dissolvable films (ODF).
Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., Maya Biotech Pvt. Ltd.
North America was the largest region in the transmucosal drug delivery devices market in 2025. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the transmucosal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the transmucosal drug delivery devices market by increasing costs of imported medical-grade polymers, microfabrication components, electronic control units, and precision manufacturing equipment. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces cost pressures on export-oriented device production. These tariffs are increasing manufacturing expenses and extending product development timelines. However, they are also encouraging domestic sourcing, localized device manufacturing, and investment in regional production facilities to improve supply chain resilience.
The transmucosal drug delivery devices market research report is one of a series of new reports that provides transmucosal drug delivery devices market statistics, including transmucosal drug delivery devices industry global market size, regional shares, competitors with a transmucosal drug delivery devices market share, detailed transmucosal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the transmucosal drug delivery devices industry. This transmucosal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Transmucosal drug delivery devices are medical instruments designed to administer drugs through mucous membranes, such as those found in the mouth, nose, or rectum, allowing for rapid absorption into the bloodstream. These devices are particularly useful for delivering medications that are poorly absorbed by the gastrointestinal tract or require swift onset of action, such as pain relief or hormone therapy. Their primary function is to circumvent the digestive system, offering a direct and efficient route for drug delivery.
The two main categories of transmucosal drug delivery devices are passive transmucosal drug delivery and active transmucosal drug delivery. Passive transmucosal drug delivery involves the absorption of drugs through mucous membranes without external energy or active transport mechanisms. Various types of products include buccal tablets, oral sprays, sublingual films, wafers, gels, medicated confectionery, among others, used for treating conditions such as pain management, addiction, and hormonal therapies. End users include academic and research institutions, pharmaceutical and biotechnology firms, diagnostic laboratories, and hospitals.
The transmucosal drug delivery devices market consists of sales of sublingual sprays, nasal drops, rectal suppositories, and sublingual tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The transmucosal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $81.52 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing development of personalized medicine solutions, rising investments in advanced drug delivery platforms, growing demand for at-home drug administration devices, expansion of biologics and peptide-based drugs, increased regulatory approvals for novel delivery systems. Major trends in the forecast period include increasing adoption of buccal and sublingual delivery formats, growing demand for rapid onset drug administration, expansion of microneedle and active delivery technologies, rising focus on patient-friendly drug delivery devices, enhanced emphasis on dose accuracy and bioavailability.
The increasing prevalence of chronic diseases is expected to drive the growth of the transmucosal drug delivery devices market in the coming years. Chronic diseases are long-lasting conditions that typically develop gradually and persist over time, often requiring ongoing medical management to control symptoms and prevent complications. The rise in chronic diseases can be attributed to factors such as lifestyle choices, aging populations, environmental influences, challenges within healthcare systems, and urbanization. Transmucosal drug delivery devices are employed in managing chronic diseases by providing controlled and efficient medication delivery, ensuring sustained therapeutic levels to manage symptoms and enhance patient adherence. For example, in August 2023, a report from the Leukemia & Lymphoma Society (LLS), a US-based nonprofit organization, indicated that in the US, a person is diagnosed with leukemia, lymphoma, or myeloma approximately every three minutes. In 2023, an estimated 184,720 individuals were expected to be diagnosed, accounting for 9.4% of the projected 1,958,310 new cancer cases for the year. Therefore, the rising prevalence of chronic diseases is fueling the growth of the transmucosal drug delivery devices market.
Leading companies in the transmucosal drug delivery devices sector are actively pursuing innovative solutions such as proprietary transdermal patch delivery platforms, which are designed to improve drug absorption, enhance patient compliance, and offer convenience. These platforms utilize specialized technologies owned by companies to administer medications through the skin, ensuring controlled release and optimized therapeutic outcomes. For example, in January 2024, Starton Therapeutics Inc., a US-based biotechnology firm, introduced STARSILON, a novel proprietary transdermal patch delivery platform. This platform is specifically designed to deliver difficult-to-formulate active pharmaceutical ingredients (APIs) over an extended period, thereby expanding the options for transdermal drug delivery and enhancing therapeutic efficacy through sustained release mechanisms.
In April 2023, Difgen Pharmaceuticals, an India-based pharmaceutical company, acquired Aveva Drug Delivery Services for an undisclosed sum. This strategic acquisition is intended to bolster Difgen Pharmaceuticals' drug delivery capabilities and incorporate advanced technologies into its pharmaceutical product portfolio. Aveva Drug Delivery Services, based in the US, specializes in manufacturing transdermal delivery systems (TDS) and oral dissolvable films (ODF).
Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., Maya Biotech Pvt. Ltd.
North America was the largest region in the transmucosal drug delivery devices market in 2025. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the transmucosal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the transmucosal drug delivery devices market by increasing costs of imported medical-grade polymers, microfabrication components, electronic control units, and precision manufacturing equipment. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces cost pressures on export-oriented device production. These tariffs are increasing manufacturing expenses and extending product development timelines. However, they are also encouraging domestic sourcing, localized device manufacturing, and investment in regional production facilities to improve supply chain resilience.
The transmucosal drug delivery devices market research report is one of a series of new reports that provides transmucosal drug delivery devices market statistics, including transmucosal drug delivery devices industry global market size, regional shares, competitors with a transmucosal drug delivery devices market share, detailed transmucosal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the transmucosal drug delivery devices industry. This transmucosal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Transmucosal drug delivery devices are medical instruments designed to administer drugs through mucous membranes, such as those found in the mouth, nose, or rectum, allowing for rapid absorption into the bloodstream. These devices are particularly useful for delivering medications that are poorly absorbed by the gastrointestinal tract or require swift onset of action, such as pain relief or hormone therapy. Their primary function is to circumvent the digestive system, offering a direct and efficient route for drug delivery.
The two main categories of transmucosal drug delivery devices are passive transmucosal drug delivery and active transmucosal drug delivery. Passive transmucosal drug delivery involves the absorption of drugs through mucous membranes without external energy or active transport mechanisms. Various types of products include buccal tablets, oral sprays, sublingual films, wafers, gels, medicated confectionery, among others, used for treating conditions such as pain management, addiction, and hormonal therapies. End users include academic and research institutions, pharmaceutical and biotechnology firms, diagnostic laboratories, and hospitals.
The transmucosal drug delivery devices market consists of sales of sublingual sprays, nasal drops, rectal suppositories, and sublingual tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Transmucosal Drug Delivery Devices Market Characteristics
3. Transmucosal Drug Delivery Devices Market Supply Chain Analysis
4. Global Transmucosal Drug Delivery Devices Market Trends and Strategies
5. Transmucosal Drug Delivery Devices Market Analysis of End Use Industries
7. Global Transmucosal Drug Delivery Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Transmucosal Drug Delivery Devices Total Addressable Market (TAM) Analysis for the Market
9. Transmucosal Drug Delivery Devices Market Segmentation
10. Transmucosal Drug Delivery Devices Market Regional and Country Analysis
11. Asia-Pacific Transmucosal Drug Delivery Devices Market
12. China Transmucosal Drug Delivery Devices Market
13. India Transmucosal Drug Delivery Devices Market
14. Japan Transmucosal Drug Delivery Devices Market
15. Australia Transmucosal Drug Delivery Devices Market
16. Indonesia Transmucosal Drug Delivery Devices Market
17. South Korea Transmucosal Drug Delivery Devices Market
18. Taiwan Transmucosal Drug Delivery Devices Market
19. South East Asia Transmucosal Drug Delivery Devices Market
20. Western Europe Transmucosal Drug Delivery Devices Market
21. UK Transmucosal Drug Delivery Devices Market
22. Germany Transmucosal Drug Delivery Devices Market
23. France Transmucosal Drug Delivery Devices Market
24. Italy Transmucosal Drug Delivery Devices Market
25. Spain Transmucosal Drug Delivery Devices Market
26. Eastern Europe Transmucosal Drug Delivery Devices Market
27. Russia Transmucosal Drug Delivery Devices Market
28. North America Transmucosal Drug Delivery Devices Market
29. USA Transmucosal Drug Delivery Devices Market
30. Canada Transmucosal Drug Delivery Devices Market
31. South America Transmucosal Drug Delivery Devices Market
32. Brazil Transmucosal Drug Delivery Devices Market
33. Middle East Transmucosal Drug Delivery Devices Market
34. Africa Transmucosal Drug Delivery Devices Market
36. Transmucosal Drug Delivery Devices Market Competitive Landscape and Company Profiles
37. Transmucosal Drug Delivery Devices Market Other Major and Innovative Companies
40. Transmucosal Drug Delivery Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Transmucosal Drug Delivery Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses transmucosal drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for transmucosal drug delivery devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The transmucosal drug delivery devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Buccal Drug Delivery Devices; Sublingual Drug Delivery Devices; Nasal Drug Delivery Devices; Rectal Drug Delivery Devices; Vaginal Drug Delivery Devices2) By Drug Type: Buccal Tablets; Oral Sprays; Sublingual Films And Wafers; Gels; Medicated Confectionery; Other Drug Types
3) By Indication: Pain Management; Addiction Treatment; Hormonal Therapies; Others Indications
4) By End User: Academic And Research Institutes; Pharmaceutical And Biotechnology Companies; Diagnostic Laboratories; Hospitals
Subsegments:
1) By Buccal Drug Delivery Devices: Mucoadhesive Buccal Tablets; Buccal Patches; Buccal Films2) By Sublingual Drug Delivery Devices: Sublingual Tablets; Sublingual Films; Sublingual Sprays
3) By Nasal Drug Delivery Devices: Metered Dose Nasal Sprays; Nasal Powder Devices; Nasal Gel Applicators
4) By Rectal Drug Delivery Devices: Rectal Suppositories; Rectal Gels
5) By Vaginal Drug Delivery Devices: Vaginal Rings; Vaginal Tablets; Vaginal Gels
Companies Mentioned: Johnson & Johnson; Bayer AG; Sanofi SA; Bristol-Myers Squibb Company; Abbott Laboratories; Novartis AG; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Catalent Inc.; AptarGroup; Glenmark Pharmaceuticals Limited; Stevanato Group S.p.A; Noven Pharmaceuticals; Antares Pharma Inc.; Satsuma Pharmaceuticals Inc.; AdvaCare Pharma LLP; Lifevision Healthcare Private Limited; SAVA Healthcare Limited; Kaizen Pharmaceuticals Pvt. Ltd.; Maya Biotech Pvt. Ltd
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Transmucosal Drug Delivery Devices market report include:- Johnson & Johnson
- Bayer AG
- Sanofi SA
- Bristol-Myers Squibb Company
- Abbott Laboratories
- Novartis AG
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Catalent Inc.
- AptarGroup
- Glenmark Pharmaceuticals Limited
- Stevanato Group S.p.A
- Noven Pharmaceuticals
- Antares Pharma Inc.
- Satsuma Pharmaceuticals Inc.
- AdvaCare Pharma LLP
- Lifevision Healthcare Private Limited
- SAVA Healthcare Limited
- Kaizen Pharmaceuticals Pvt. Ltd.
- Maya Biotech Pvt. Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 59.61 Billion |
| Forecasted Market Value ( USD | $ 81.52 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
